Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; Escherichia coli 0157
CPT4 code
Name of the Procedure:
Infectious agent antigen detection by immunoassay technique, commonly referred to as Enzyme Immunoassay (EIA), Enzyme-linked Immunosorbent Assay (ELISA), or Immunochemiluminometric Assay (IMCA); for Escherichia coli 0157.
Summary
This test detects the presence of antigens specific to the Escherichia coli O157 bacteria through various immunoassay techniques. It identifies the bacteria by recognizing antigenic components, either qualitatively (presence or absence) or semiquantitatively, via a multiple-step method.
Purpose
The test is designed to diagnose infections caused by the Escherichia coli O157 strain. The main goals are to confirm infection, guide treatment, and prevent complications from untreated E. coli infections, such as hemolytic uremic syndrome.
Indications
- Symptoms of severe gastrointestinal distress, such as bloody diarrhea or abdominal cramps.
- Recent consumption of potentially contaminated food or water.
- Exposure to an E. coli outbreak.
- Immunocompromised patients presenting with gastrointestinal symptoms.
Preparation
- No specific fasting requirements or dietary restrictions.
- Inform the healthcare provider of any medications being taken, including antibiotics.
- Follow instructions for sample collection if the patient will collect it themselves (usually a stool sample).
Procedure Description
- Sample Collection: A stool sample is usually collected either in a healthcare setting or by the patient at home.
- Sample Preparation: The sample is prepared and treated in a laboratory to isolate potential antigenic components.
- Immunoassay Application: The prepared sample undergoes immunoassay, where it is exposed to antibodies specific to E. coli antigens.
- EIA/ELISA: Uses enzyme-linked antibodies that produce a color change when antigen binding occurs.
- IMCA: Involves chemiluminescent labels that emit light upon binding with the target antigen.
- Detection and Analysis: The results are observed and measured either qualitatively or semiquantitatively.
Duration
The entire assay process typically takes several hours to a day, depending on the lab's protocols.
Setting
Performed in a clinical laboratory setting equipped for immunoassays.
Personnel
- Medical Laboratory Technologists or Technicians.
- Microbiologists or Clinical Laboratory Scientists.
- Pathologists for result interpretation.
Risks and Complications
- Minimal risk associated with the test.
- Rarely, improper sample collection can lead to inaccurate results, necessitating a repeat test.
Benefits
- Accurate identification of E. coli O157 strain.
- Guides appropriate antibiotic therapy.
- Helps prevent severe complications.
- Results typically available within a day.
Recovery
- No physical recovery needed as it's a non-invasive test.
- Follow-up based on results and clinician's recommendations.
Alternatives
- Polymerase Chain Reaction (PCR) tests for bacterial DNA, which may be faster but more expensive.
- Culture-based methods, which are slower and require skilled interpretation, but can provide additional antimicrobial sensitivity information.
Patient Experience
- If collecting the sample yourself, follow detailed instructions for hygiene and container use.
- Minimal discomfort in sample collection.
- Results will be communicated by the healthcare provider, who will also discuss any further steps or treatments based on the outcomes.